C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
| CCCC Stock | USD 2.65 0.14 5.02% |
About 60% of C4 Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that many traders are alarmed. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
CCCC |
Clinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 -- C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer , in
Read at finance.yahoo.com
 |
C4 Therapeutics Fundamental Analysis
We analyze C4 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
C4 Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
C4 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C4 Therapeutics stock to make a market-neutral strategy. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with similar companies.
Peers
C4 Therapeutics Related Equities
| MLYS | Mineralys Therapeutics, | 10.50 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| GLUE | Monte Rosa | 1.03 | ||||
| CGEM | Cullinan Oncology | 1.29 | ||||
| IPSC | Century Therapeutics | 1.43 | ||||
| KYMR | Kymera Therapeutics | 1.70 | ||||
| FHTX | Foghorn Therapeutics | 1.76 | ||||
| RVMD | Revolution Medicines | 2.03 | ||||
| NRIX | Nurix Therapeutics | 2.31 | ||||
| PRLD | Prelude Therapeutics | 2.41 | ||||
| ARVN | Arvinas | 3.00 | ||||
| RZLT | Rezolute | 3.46 | ||||
| STTK | Shattuck Labs | 24.61 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |